Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MT-ND2 pseudogene 9 (MTND2P9) is a nuclear pseudogene and does not encode a functional protein product. It is homologous to the mitochondrial MT-ND2 gene (mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2), which encodes an essential subunit of Complex I in the mitochondrial electron transport chain responsible for electron transfer from NADH to ubiquinone[8][12]. Pseudogenes like MTND2P9 do not perform these functions and are generally not considered therapeutic targets. There is no evidence for a direct biological function, role in disease, or interactions with drugs for this pseudogene, making it irrelevant as a therapeutic target. Its presence in the genome may be of research interest for evolutionary studies or transcriptomic analyses but does not hold direct clinical significance as a target[13][8][12][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 pseudogene 9 (MTND2P9).